First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects

美罗培南 耐受性 药代动力学 药效学 医学 药理学 人口 加药 不利影响 内科学 麻醉 抗生素 生物 微生物学 抗生素耐药性 环境卫生
作者
Zhiwei Huang,Xinyi Yang,Yi Jiang,Jingwei Yu,Guoying Cao,Jingjing Wang,Yingying Hu,Jing-Yi Dai,Jufang Wu,Qiong Wei,Ye Tian,Shu‐Yan Yu,Xu Zhu,Xiaomeng Mao,Wei Liu,Hong Liang,Shansong Zheng,Yun Huei Ju,Zenghua Wang,Jing Zhang,Xiaojie Wu
出处
期刊:Antimicrobial Agents and Chemotherapy [American Society for Microbiology]
被引量:1
标识
DOI:10.1128/aac.01330-23
摘要

ABSTRACT FL058 is a novel diazabicyclooctane β-lactamase inhibitor. This first-in-human study evaluated the safety, tolerability, and population pharmacokinetic (PK)/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects. The results showed that the maximum tolerated dose of FL058 was 3,000 mg after single-dose infusion. FL058 in combination with meropenem did not cause any grade 3 or higher adverse event when the dose was escalated up to 1,000 mg/2,000 mg. FL058 exposure PK parameters showed dose proportionality. FL058 was excreted primarily in urine. No significant PK interaction was found between FL058 and meropenem. Population PK model analysis indicated that the PK profiles of FL058 and meropenem were consistent with the two-compartment model. The impact of covariates, creatinine clearance, concomitant use of meropenem, body weight, sex, and FL058 dose, on FL058 exposure was less than 10%. FL058/meropenem combination was safe and well tolerated up to a 1,000-mg/2,000-mg dose in healthy adults. The recommended minimum dose of FL058/meropenem combination was 500 mg/1,000 mg by intravenous infusion over 2 h every 8 h based on target attainment analysis. The good safety, tolerability, and satisfactory PK profiles of FL058 alone and in combination with meropenem in this first-in-human study will support further clinical development of FL058 in combination with meropenem in patients with target infections (ClinicalTrials.gov identifiers: NCT05055687, NCT05058118, and NCT05058105).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ric发布了新的文献求助10
刚刚
失眠鸭完成签到,获得积分10
1秒前
流水应助安静的芷天采纳,获得10
1秒前
1秒前
粒粒完成签到,获得积分10
1秒前
1秒前
1秒前
见祥雨完成签到,获得积分10
1秒前
keyantongxiaosen完成签到,获得积分10
1秒前
top发布了新的文献求助10
2秒前
自然1111发布了新的文献求助10
2秒前
2秒前
熊98完成签到,获得积分10
3秒前
Owen应助罗永昊采纳,获得10
3秒前
6秒前
6秒前
爆米花应助一方通行采纳,获得10
6秒前
6秒前
猫独秀完成签到,获得积分10
6秒前
7秒前
THEEVE发布了新的文献求助30
7秒前
萧水白应助ak采纳,获得10
7秒前
7秒前
蒙蒙完成签到 ,获得积分10
7秒前
懂得珍惜完成签到,获得积分20
7秒前
方元浡完成签到,获得积分10
7秒前
咿呀咿呀哟应助yooloo采纳,获得30
7秒前
Lucas应助Justtry采纳,获得10
8秒前
花痴的沂完成签到,获得积分10
8秒前
学医的小胖子完成签到 ,获得积分10
9秒前
9秒前
10秒前
Bethune发布了新的文献求助30
10秒前
11秒前
emma发布了新的文献求助10
11秒前
动听红牛发布了新的文献求助10
11秒前
希望天下0贩的0应助蒺藜采纳,获得10
11秒前
woobinhua发布了新的文献求助10
12秒前
May应助北彧采纳,获得10
12秒前
12秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961223
求助须知:如何正确求助?哪些是违规求助? 3507496
关于积分的说明 11136509
捐赠科研通 3239958
什么是DOI,文献DOI怎么找? 1790571
邀请新用户注册赠送积分活动 872449
科研通“疑难数据库(出版商)”最低求助积分说明 803186